SCHEMBL12707404

SCHEMBL12707404

Cc1ccc(N)cc1-c1cnccc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G7 Q13093 1/20 0.44
PTGS2 P35354 1/20 0.40
ALDH1A1 P00352 1/20 0.39
ABL1 P00519 1/20 0.39
TDO2 P48775 2/20 0.38
CASP1 P29466 2/20 0.38
CYP11B1 P15538 3/20 0.37
CYP11B2 P19099 3/20 0.37
RPS6KA3 P51812 2/20 0.37
PDE10A Q9Y233 2/20 0.36
CYP3A4 P08684 3/20 0.36
TSHR P16473 1/20 0.36
ADRA2B P18089 1/20 0.36
CYP1A2 P05177 2/20 0.35
CYP2E1 P05181 2/20 0.35
CYP2C8 P10632 2/20 0.35
CYP2D6 P10635 2/20 0.35
CYP2A6 P11509 2/20 0.35
CYP2C9 P11712 2/20 0.35
CYP2B6 P20813 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL527540 0.87 ALDH1A1 (0.39) PTGS2ALDH1A1ABL1TDO2CASP1
SCHEMBL12707407 0.86 PLA2G7 (0.49) PLA2G7PTGS2ALDH1A1ABL1TDO2
SCHEMBL7085707 0.83 ADRA2B (0.37) CYP11B1CYP11B2RPS6KA3CYP3A4ADRA2B
SCHEMBL12707403 0.80 PTGS2 (0.40) PTGS2TDO2CYP11B1CYP11B2RPS6KA3
SCHEMBL2893826 0.77 PLA2G7 (0.60) PLA2G7ALDH1A1ABL1TDO2CASP1
SCHEMBL7086302 0.76 ABL1 (0.44) PLA2G7PTGS2ALDH1A1ABL1TDO2
SCHEMBL31607621 0.75 PLA2G7 (0.65) PLA2G7ALDH1A1CASP1PDE10ACYP3A4
SCHEMBL8848693 0.75 PLA2G7 (0.65) PLA2G7ALDH1A1CASP1PDE10ACYP3A4
SCHEMBL30092397 0.75 PLA2G7 (0.65) PLA2G7ALDH1A1CASP1PDE10ACYP3A4
SCHEMBL527609 0.74 ABL1 (0.45) PTGS2ALDH1A1ABL1TDO2CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110082147-A1 SUBSTITUTED IMIDAZOTRIAZINES CONCERT PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110082147-A1 SUBSTITUTED IMIDAZOTRIAZINES GABRA5, GABRA3, GABRA2 PLA2G7 1779/4885PTGS2 1242/4885ALDH1A1 881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.